Mirum Pharmaceuticals (NASDAQ:MIRM) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Mirum Pharmaceuticals (NASDAQ:MIRM) from a hold rating to a sell rating in a research report released on Saturday.

Several other research firms have also recently weighed in on MIRM. Leerink Partners lowered their price target on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. Royal Bank Of Canada raised their price target on Mirum Pharmaceuticals from $128.00 to $142.00 and gave the company an “outperform” rating in a report on Thursday. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $165.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday. Robert W. Baird raised their price target on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Weiss Ratings raised Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $136.42.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $107.16 on Friday. The stock’s 50-day simple moving average is $93.79 and its 200 day simple moving average is $86.06. Mirum Pharmaceuticals has a 52-week low of $42.89 and a 52-week high of $112.00. The stock has a market capitalization of $6.53 billion, a price-to-earnings ratio of -7.87 and a beta of 0.52. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 10.84%. The business had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. During the same period in the previous year, the business earned ($0.30) EPS. The business’s revenue was up 43.3% on a year-over-year basis. Research analysts forecast that Mirum Pharmaceuticals will post -8.25 EPS for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, insider Joanne Quan sold 7,287 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $670,258.26. Following the transaction, the insider directly owned 18,864 shares in the company, valued at $1,735,110.72. This trade represents a 27.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jolanda Howe sold 4,732 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $435,249.36. Following the transaction, the senior vice president owned 8,429 shares in the company, valued at approximately $775,299.42. The trade was a 35.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 76,806 shares of company stock worth $7,064,616 over the last quarter. Company insiders own 14.36% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Emerald Advisers LLC grew its position in Mirum Pharmaceuticals by 20.9% during the 3rd quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock worth $27,095,000 after acquiring an additional 63,834 shares during the last quarter. Candriam S.C.A. grew its position in Mirum Pharmaceuticals by 8.0% during the 3rd quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock worth $29,546,000 after acquiring an additional 30,021 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Mirum Pharmaceuticals in the 4th quarter worth approximately $1,478,000. TimesSquare Capital Management LLC purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter worth approximately $22,041,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter worth approximately $808,000.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum jumped after investors reacted to positive Volixibat Phase 2b data in primary sclerosing cholangitis (PSC), which supports the company’s pipeline and has likely improved confidence in future growth. Mirum Pharmaceuticals (MIRM) Is Up 16.9% After Volixibat Phase 2b PSC Itch Data And Big Q1 Loss – Has The Bull Case Changed?
• Positive Sentiment: HC Wainwright raised its FY2027 earnings estimate for Mirum Pharmaceuticals to $0.70 per share from $0.63, suggesting stronger longer-term profitability expectations.
• Positive Sentiment: The firm also lifted its Q4 2026 EPS estimate to a smaller loss of $(0.06) from $(0.09), which points to improving near-term earnings momentum.
• Neutral Sentiment: HC Wainwright now expects Mirum to turn profitable in later periods, including $0.02 EPS in Q2 2027, $0.26 in Q3 2027, and $0.49 in Q4 2027, reinforcing a more constructive long-term view.
• Negative Sentiment: Despite the improved outlook, the analyst still sees losses through most of 2026, including a larger Q2 2026 loss estimate of $(0.58) and a Q3 2026 loss estimate of $(1.06), highlighting that profitability remains some time away.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.